Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multicenter randomized blinded trial of adamgammadex sodium for reversal of rocuronium-induced neuromuscular blockade at T2 reappearance
ChiCTR2000033548Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adamgammadex in reversal of nondepolarizing neuromuscular blockade (5 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Time from administration to TOF ratio recovery to 0.9, Safety assessment and 1 more. Started Jul 2018; status: recruiting.
02
Drugs
adamgammadex
03
Conditions
reversal of nondepolarizing neuromuscular blockade
Beyond the preview
Go deeper on ChiCTR2000033548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033548.